Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ivermectin

ivermectin

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ivermectin

23 trials tracked of ivermectin: 15 in phase 3 or 4 and 9 with published results. The most-cited published study has 245 citations.

23Trials tracked
15Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 3 Phase 3 12 Phase 2 6 Phase 1 2
  1. Phase 3 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) Completed · 245 cited
  2. Phase 3 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed · 141 cited
  3. Phase 4 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Completed · 71 cited
  4. Phase 3 Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis Completed · 48 cited
  5. Phase 4 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis Completed · 42 cited
  6. Phase 3 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands Completed · 25 cited
Show 17 more trials
  1. Phase 3 Repeat Ivermectin Mass Drug Administrations for MALaria Control II Completed · 21 cited
  2. Phase 3 Moxidectin for LF, Cote d'Ivoire (DOLF) Completed · 10 cited
  3. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications Completed · 5 cited
  4. Phase 4 Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events Completed
  5. Phase 3 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Completed
  6. Phase 3 Ivermectin for Severe COVID-19 Management Completed
  7. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) Completed
  8. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) Completed
  9. Phase 3 Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole Completed
  10. Phase 2 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients Completed
  11. Phase 2 Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms Completed
  12. Phase 2 Development of Ivermectin for Alcohol Use Disorders Completed
  13. Phase 2 Rosacea and Ivermectin Completed
  14. Phase 2 Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation. Completed
  15. Phase 2 Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial Completed
  16. Phase 1 Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19 Completed
  17. Phase 1 Ivermectin and Human Immunity Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of ivermectin MDA for onchocerciasis and hookworm co-infections in endemic regions
Neurology Sys. Review
Review of ivermectin MDA for onchocerciasis and hookworm co-infections in endemic regions Ivermectin helps clear hookworm even when people also carry river blindness
This narrative review synthesizes evidence on preventative chemotherapy and Mass Drug Administration with ivermectin for onchocerciasis and …
A review shows ivermectin treatment improves outcomes for people infected with both river blindness and hookworm, though more data on immune…
Frontiers May 16, 2026
Meta-analysis shows integrated MDA reduces yaws attendances in Papua New Guinea
Infectious Disease Meta-analysis
Meta-analysis shows integrated MDA reduces yaws attendances in Papua New Guinea Four-drug treatment lowered yaws cases in Papua New Guinea communities significantly
This comparative observational study and systematic review with network meta-analysis evaluates yaws control strategies in under-reached com…
A new review shows that giving four medicines together greatly reduced yaws cases in Papua New Guinea. People saw fewer skin problems and fe…
May 14, 2026
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Infectious Disease Phase III
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial Metformin Cuts Long Covid Risk by 40%
This randomized controlled trial in 1323 non-hospitalized adults with SARS-CoV-2 infection evaluated metformin, fluvoxamine, or ivermectin v…
A common diabetes pill taken early in Covid infection cuts the odds of developing long-term symptoms by 40%, offering new hope for millions.
CT.gov Apr 24, 2026
Cross-sectional review of mass drug administration impact on lymphatic filariasis elimination in Nepal
Infectious Disease
Cross-sectional review of mass drug administration impact on lymphatic filariasis elimination in Nepal Mass drug administration reduces lymphatic filariasis in most Nepal districts
This cross-sectional epidemiological monitoring survey review assesses lymphatic filariasis transmission in six endemic districts of Nepal f…
A survey of over 7,000 people in Nepal found that mass drug administration lowered infection rates in most areas, though three sites still n…
medRxiv Apr 24, 2026